US20080058381A1 - Combination of a cb1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity - Google Patents

Combination of a cb1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity Download PDF

Info

Publication number
US20080058381A1
US20080058381A1 US11/937,121 US93712107A US2008058381A1 US 20080058381 A1 US20080058381 A1 US 20080058381A1 US 93712107 A US93712107 A US 93712107A US 2008058381 A1 US2008058381 A1 US 2008058381A1
Authority
US
United States
Prior art keywords
methyl
chlorophenyl
bis
azetidine
methylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/937,121
Inventor
Odile Piot-Grosjean
Philippe Picaut
Francois Petitet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0012646A external-priority patent/FR2814678B1/en
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Priority to US11/937,121 priority Critical patent/US20080058381A1/en
Publication of US20080058381A1 publication Critical patent/US20080058381A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Abstract

The present invention relates to the combination of a CB1 receptor antagonist and of sibutramine, to the pharmaceutical compositions comprising them and to their use in the treatment of obesity.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of U.S. application Ser. No. 11/461,468, filed Aug. 1, 2006, now pending, which is a continuation of U.S. application Ser. No. 10/941,242, filed Sep. 15, 2004, now U.S. Pat. No. 7,148,258, issued Dec. 12, 2006, which is a division of Ser. No. 09/968,903, filed Oct. 3, 2001, now abandoned, which claims the benefit of U.S. Provisional Application No. 60/244,187, filed Oct. 31, 2000, all of which are incorporated herein by reference in their entirety; which claims the benefit of priority of French Patent Application No. 00/12,646, filed Oct. 4, 2000.
    • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The present invention relates to the combination of a CB1 receptor antagonist and of sibutramine, to the pharmaceutical compositions comprising them and to their use in the treatment of obesity.
  • 2. Description of the Art
  • CB1 receptor antagonists are known for their effect on food intake and their use as anorexigenic (G. Colombo et al., Life Sciences, 63 (8), 113-117 (1998); J. Siamand et al., Behavioural Pharmacol., 9, 179-181 (1998)).
  • Sibutramine (BTS 54524; N-{1-[1-(4-chloro-phenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine; MeridiaR, ReductilR), its hydrate and its pharmaceutically acceptable salts and in particular its hydrochloride reduces food intake and is of use in the treatment of obesity (WO 90/061110; D. H. Ryan et al., Obesity Research, 3 (4), 553 (1995); H. C. Jackson et al., British Journal of Pharmacology, 121, 1758 (1997); G. Fanghanel et al., Inter. J. Obes., 24 (2), 144 (2000); G. A. Bray et al., Obes. Res., 7 (2), 189 (1999)).
    • SUMMARY OF THE INVENTION
  • It has now been found that the combination of sibutramine, its hydrate and its pharmaceutically acceptable salts and of a CB1 receptor antagonist exhibits a synergistic effect in reducing food consumption and is thus of use in the treatment of obesity.
  • The combination can also comprise several CB1 receptor antagonists.
    • DETAILED DESCRIPTION OF THE INVENTION
  • Use may in particular be made, among CB1 receptor antagonists, of the azetidine derivatives disclosed in WO 00/15609, WO 01/64633 and WO 01/64634 of formula:
    Figure US20080058381A1-20080306-C00001
  • in which
  • either R represents a chain (A) or (B) and
    Figure US20080058381A1-20080306-C00002
  • R1 represents a methyl or ethyl radical,
  • R2 represents either an aromatic chosen from phenyl, naphthyl or indenyl, these aromatics being unsubstituted or substituted by one or more halogen, alkyl, alkoxy, —CO-alk, hydroxyl, —COOR5, formyl, trifluoromethyl, trifluoromethylsulfanyl, trifluoromethoxy, nitro, —NR6R7, —CO—NH—NR6R7, —N(alk)COOR8, cyano, —CONHR9, —CO—NR16R17, alkylsulfanyl, hydroxyalkyl, —O-alk-NR12R13 or alkylthioalkyl, or a heteroaromatic chosen from the benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydrobenzofuryl, 2,3-dihydrobenzothienyl, indolinyl, indolyl, isochromanyl, isoquinolyl, pyridyl, quinolyl, 1,2,3,4-tetrahydroisoquinolyl, 1,2,3,4-tetrahydroquinolyl, thiazolyl or thienyl rings, it being possible for these heteroaromatics to be unsubstituted or substituted by a halogen, alkyl, alkoxy, —COOR5, trifluoromethyl, trifluoromethylsulfanyl, trifluoromethoxy, nitro, —NR6R7, —CO—NH—NR6R7, cyano, —CONHR9, alkylsulfanyl, hydroxyalkyl or alkylthioalkyl,
  • R3 and R4, which are identical or different, represent either an aromatic chosen from phenyl, naphthyl or indenyl, these aromatics being unsubstituted or substituted by one or more halogen, alkyl, alkoxy, formyl, hydroxyl, trifluoromethyl, trifluoromethoxy, —CO-alk, cyano, —COOR5, —CONR10R11, —CO—NH—NR6R7, alkylsulfanyl, hydroxyalkyl, -alk-NR6R7 or alkylthioalkyl, or a heteroaromatic chosen from the benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydrobenzofuryl, 2,3-dihydro-benzothienyl, furyl, isochromanyl, isoquinolyl, pyrrolyl, quinolyl, 1,2,3,4-tetrahydroisoquinolyl, thiazolyl or thienyl rings, it being possible for these heteroaromatics to be unsubstituted or substituted by a halogen, alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, —COOR5, —CO—NH—NR6R7, —CONR10R11, alk-NR6R7, alkylsulfanyl, hydroxyalkyl or alkylthioalkyl,
  • R5 is an alkyl radical or a phenyl radical optionally substituted by one or more halogen atoms,
  • R6 and R7, which are identical or different, represent a hydrogen atom or an alkyl, —COOalk, cycloalkyl, alkylcycloalkyl, -alk-O-alk or hydroxyalkyl radical or else R6 and R7 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl, —COalk, —COOalk, —CO—NHalk, —CS—NHalk, —CO-alk-NR14R15, oxo, hydroxyalkyl, -alk-O-alk or —CO—NH2 radicals,
  • R8 represents an alkyl radical,
  • R9 represents a hydrogen atom or a radical of the type alkyl or alkyl substituted by dialkylamino, phenyl, cycloalkyl (optionally substituted by —COOalk) or a saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising one or more heteroatoms chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl radicals,
  • R10 and R11, which are identical or different, represent a hydrogen atom or an alkyl radical or else R10 and R11 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by an alkyl radical,
  • R12 and R13, which are identical or different, represent a hydrogen atom or an alkyl or cycloalkyl radical or else R12 and R13 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by an alkyl, —COalk, —COOalk, —CO—NHalk, —CS—NHalk or —CO-alk-NR14R15 radical or a saturated mono- or bicyclic heterocycle having 3 to 10 ring members and comprising a heteroatom chosen from oxygen, sulfur and nitrogen,
  • R14 and R15, which are identical or different, represent a hydrogen atom or an alkyl or —COOalk radical,
  • R16 and R17 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen,
  • R′ represents a hydrogen atom or a —CO-alk radical,
  • or R represents a CHR18 radical and
  • R18 represents an —NHCOR19 or —N(R20)—Y—R21 radical,
  • Y is CO or SO2,
  • R4 and R3, which are identical or different, represent either an aromatic chosen from phenyl, naphthyl and indenyl, these aromatics being unsubstituted or substituted by one or more halogen, alkyl, alkoxy, formyl, hydroxyl, trifluoromethyl, trifluoromethoxy, —CO-alk, cyano, —COOH, —COOalk, —CONR22R23, —CO—NH—NR24R25, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, hydroxyalkyl or -alk-NH22R23, or a heteroaromatic chosen from the benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydrobenzofuryl, 2,3-dihydrobenzothienyl, pyrimidinyl, furyl, imidazolyl, isochromanyl, isoquinolyl, pyrrolyl, pyridyl, quinolyl, 1,2,3,4-tetrahydroisoquinolyl, thiazolyl and thienyl rings, it being possible for these heteroaromatics to be unsubstituted or substituted by a halogen, alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, —COOH, —COOalk, —CO—NH—NR24R25, —CONR22R23, -alk-NR24R25, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl or hydroxyalkyl,
  • R19 represents an -alk-SO2—R26 radical, an -alk-SO2—CH═CH—R26 radical, a Het1 radical substituted by —SO2—R26 or a phenyl radical substituted by —SO2—R26 or -alk-SO2—R26,
  • R20 represents a hydrogen atom or an alkyl radical,
  • R21 represents a phenylalkyl, Het1 or Ar1 radical,
  • R22 and R23, which are identical or different, represent a hydrogen atom or an alkyl radical or else R22 and R23 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl,
  • R24 and R25, which are identical or different, represent a hydrogen atom or an alkyl, —COOalk, cycloalkyl, alkylcycloalkyl, -alk-O-alk or hydroxyalkyl radical or else R24 and R25 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl, —COalk, —COOalk, —CO—NHalk, —CS—NHalk, oxo, hydroxyalkyl, -alk-O-alk or —CO—NH2,
  • R26 represents an alkyl, Ar1 or Het1 radical,
  • Ar1 represents a phenyl, naphthyl or indenyl radical, these radicals optionally being substituted by one or more halogen, alkyl, alkoxy, cyano, —CO-alk, —COOH, —COOalk, —CONR27R28, —CO—NH—NR29R30, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, -alk-NR29R30, —NR29R30, alkylthioalkyl, formyl, hydroxyl, hydroxyalkyl, Het, —O-alk-NH-cycloalkyl, OCF3, CF3, —NH—CO-alk, —SO2NH2, —NH—COCH3, —NH—COOalk or Het or else on 2 adjacent carbon atoms by dioxymethylene,
  • Het1 represents an unsaturated or saturated mono- or bicyclic heterocycle having 3 to 10 ring members and comprising one or more heteroatoms chosen from oxygen, sulfur and nitrogen which is optionally substituted by one or more alkyl, alkoxy, vinyl, halogen, alkoxycarbonyl, oxo, hydroxyl, OCF3 or CF3, the nitrogenous heterocycles optionally being in their N-oxidized form,
  • R27 and R28, which are identical or different, represent a hydrogen atom or an alkyl radical or else R27 and R28 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl radicals,
  • R29 and R30, which are identical or different, represent a hydrogen atom or an alkyl, —COOalk, cycloalkyl, alkylcycloalkyl, -alk-O-alk or hydroxyalkyl radical or else R29 and R30 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl, —COalk, —COOalk, —CO—NHalk, —CS—NHalk, oxo, hydroxyalkyl, -alk-O-alk or —CO—NH2 radicals,
  • or R represents CHR31 and
  • R31 represents an —N(R32)R33, —N(R32)—CO—R33 or —N(R32)—SO2R34 radical,
  • R4 and R3, which are identical or different, represent either an aromatic chosen from phenyl, naphthyl and indenyl, these aromatics being unsubstituted or substituted by one or more halogen, alkyl, alkoxy, formyl, hydroxyl, trifluoromethyl, trifluoromethoxy, —CO-alk, cyano, —COOH, COOalk, —CONR22R23, —CO—NH—NR24R25, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, hydroxyalkyl or -alk-NR7R8, or a heteroaromatic chosen from the benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydrobenzofuryl, 2,3-dihydrobenzothienyl, furyl, imidazolyl, isochromanyl, isoquinolyl, pyrrolyl, pyridyl, pyrimidyl, quinolyl, 1,2,3,4-tetra-hydroisoquinolyl, thiazolyl and thienyl rings, it being possible for these heteroaromatics to be unsubstituted or substituted by a halogen, alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, —COOH, —COOalk, —CO—NH—NR24R25, —CONR22R23, -alk-NR24R25, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl or hydroxyalkyl,
  • R32 represents a —C(R35)(R36)—Het2, -Het2, —C(R35)(R36)-Ar2, Ar2, cycloalkyl or norbornyl radical,
  • R33 represents a hydrogen atom or a hydroxyalkyl, -alk-COOalk, -alk-CONR22R23, -alk-NR22R23, alkoxy, Ar2, Het2, —CH2Ar2, —CH2Het2 or alkyl radical, the latter optionally substituted by one or more halogen,
  • R34 represents a hydroxyalkyl, -alk-COOalk, -alk-CONR22R23, -alk-NR22R23, alkoxy, Ar2, Het2, —CH2Ar2, —CH2Het2 or alkyl radical, the latter optionally substituted by one or more halogen,
  • R35 represents a hydrogen atom or a hydroxyalkyl, -alk-COOalk, -alk-CONR22R23, -alk-NR22R23, alkoxyalkyl, Ar2, Het2, —CH2Ar2, —CH2Het2 or alkyl radical, the latter optionally substituted by one or more halogen,
  • R36 represents a hydrogen atom or a hydroxyalkyl, -alk-COOalk, -alk-CONR22R23, -alk-NR22R23, alkoxyalkyl or alkyl radical, the latter optionally substituted by one or more halogen,
  • or else R35 and R36 form, together with the carbon atom to which they are attached, a saturated mono- or bicyclic ring having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl,
  • Ar2 represents a phenyl, naphthyl or indenyl radical, these various radicals optionally being substituted by one or more halogen, alkyl, alkoxy, —CO-alk, cyano, —COOH, —COOalk, —CONR37R38, —CO—NH—R39R40, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, -alk-NR39R40, —NR39R40, alkylthioalkyl, formyl, CF31 OCF3, Het, —O-alk-NH-cycloalkyl, SO2NH2, hydroxyl, hydroxyalkyl, —NHCOalk or NHCOOalk or on 2 adjacent carbon atoms by dioxymethylene,
  • Het2 represents an unsaturated or saturated mono- or bicyclic heterocycle having 3 to 10 ring members and comprising one or more heteroatoms chosen from oxygen, sulfur and nitrogen which is optionally substituted by one or more alkyl, alkoxy, halogen, alkoxycarbonyl, oxo or hydroxyl, the nitrogenous heterocycles optionally being in their N-oxidized form,
  • R37 and R38, which are identical or different, represent a hydrogen atom or an alkyl radical or else R37 and R38 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl,
  • R39 and R40, which are identical or different, represent a hydrogen atom or an alkyl radical or else R39 and R40 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl,
  • alk represents an alkyl or alkylene radical,
  • the alkyl and alkylene radicals and portions and the alkoxy radicals and portions have straight or branched chains and comprise 1 to 6 carbon atoms and the cycloalkyl radicals comprise 3 to 10 carbon atoms,
  • the optical isomers of these compounds and their pharmaceutically acceptable salts with an inorganic or organic acid.
  • The preferred azetidine derivatives are as follows:
    • 1-benzhydryl-3-[(methylsulfonyl)(phenyl)-methylene]azetidine,
    • 1-benzhydryl-3-[(3-methylphenyl)(methylsulfonyl)-methylene]azetidine,
    • 1-benzhydryl-3-[(3-chlorophenyl)(methylsulfonyl)-methylene]azetidine,
    • 1-benzhydryl-3-[(3,5-dichlorophenyl)(methylsulfonyl)-methylene]azetidine,
    • 1-benzhydryl-3-[(2,5-dichlorophenyl)(methylsulfonyl)-methylene]azetidine,
    • 1-benzhydryl-3-[(2,3-dichlorophenyl)(methylsulfonyl)-methylene]azetidine,
    • 1-benzhydryl-3-[(3-fluorophenyl)(methylsulfonyl)-methylene]azetidine,
    • 1-benzhydryl-3-[(3,5-difluorophenyl)(methylsulfonyl)-methylene]azetidine,
    • 1-benzhydryl-3-[(3-bromophenyl)(methylsulfonyl)-methylene]azetidine,
    • 1-benzhydryl-3-[(3-iodophenyl)(methylsulfonyl)-methylene]azetidine,
    • 1-benzhydryl-3-[(methylsulfonyl)(3-trifluoro-methoxyphenyl)methylene]azetidine,
    • 1-benzhydryl-3-[(methylsulfonyl)(3-trifluoro-methylphenyl)methylene]azetidine,
    • 1-benzhydryl-3-{[3,5-bis(trifluoromethyl)phenyl]-(methylsulfonyl)methylene}azetidine,
    • 1-benzhydryl-3-[(3,5-dibromophenyl)(methylsulfonyl)-methylene]azetidine,
    • 1-benzhydryl-3-[(3-methoxycarbonylphenyl)-(methylsulfonyl)methylene]azetidine,
    • 1-benzhydryl-3-[(3-cyanophenyl)(methylsulfonyl)-methylene]azetidine,
    • 1-benzhydryl-3-[(3-carbamoylphenyl)(methylsulfonyl)-methylene]azetidine,
    • 1-benzhydryl-3-[(methylsulfonyl)(naphth-1-yl)(methyl-sulfonyl)methylene]azetidine,
    • 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine,
    • 1-[bis(4-methoxyphenyl)methyl]-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine,
    • 1-[bis(4-methylphenyl)methyl]-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine,
    • (RS)-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-1-[(4-methoxyphenyl)(phenyl)methyl)]azetidine,
    • (R)-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-1-[(4-methoxyphenyl)(phenyl)methyl]azetidine,
    • (S)-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-1-[(4-methoxyphenyl)(phenyl)methyl]azetidine,
    • 1-[bis(4-trifluoromethoxyphenyl)methyl]-3-[(3,5-di-fluorophenyl)(methylsulfonyl)methylene]azetidine,
    • 1-[bis(4-trifluoromethylphenyl)methyl]-3-[(3,5-di-fluorophenyl)(methylsulfonyl)methylene]azetidine,
    • 1-[bis(4-chlorophenyl)methyl]-3-{[3,5-bis(trifluoro-methyl)phenyl]methylsulfonylmethylene}azetidine,
    • (RS)-1-[(4-chlorophenyl)(2,4-dichlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)-methylene]azetidine,
    • (R)-1-[(4-chlorophenyl)(2,4-dichlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)-methylene]azetidine,
    • (S)-1-[(4-chlorophenyl)(2,4-dichlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)-methylene]azetidine,
    • (RS)-1-{(4-chlorophenyl)[4-(hydroxymethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine,
    • (R)-1-{(4-chlorophenyl)[4-(hydroxymethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine,
    • (S)-1-{(4-chlorophenyl)[4-(hydroxymethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine,
    • (RS)-1-{(4-chlorophenyl)[4-(pyrrolidylmethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine,
    • (R)-1-{(4-chlorophenyl)[4-(pyrrolidylmethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine,
    • (S)-1-{(4-chlorophenyl)[4-(pyrrolidylmethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine,
    • 1-{(RS)-(4-chlorophenyl)[4-(3,3-dimethylpiperidin-1-ylmethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine,
    • 1-{(R)-(4-chlorophenyl)[4-(3,3-dimethylpiperidin-1-ylmethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine,
    • 1-{(S)-(4-chlorophenyl)[4-(3,3-dimethylpiperidin-1-ylmethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine,
    • 1-{(RS)-(4-chlorophenyl)[4-(thiomorpholin-4-ylmethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine,
    • 1-{(R)-(4-chlorophenyl)[4-(thiomorpholin-4-ylmethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine,
    • 1-{(S)-(4-chlorophenyl)[4-(thiomorpholin-4-ylmethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine,
    • 1-{(RS)-(4-chlorophenyl)[4-(N-ethyl-N-cyclohexylaminomethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine,
    • 1-{(R)-(4-chlorophenyl)[4-(N-ethyl-N-cyclohexylaminomethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine,
    • 1-{(S)-(4-chlorophenyl)[4-(N-ethyl-N-cyclohexylaminomethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine,
    • 1-{{(RS)-(4-chlorophenyl){4-[(4-ethoxycarbonyl-piperazinyl)methyl]phenyl}methyl}}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine,
    • 1-{{(R)-(4-chlorophenyl){4-[(4-ethoxycarbonyl-piperazinyl)methyl]phenyl}methyl}}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine,
    • 1-{{(S)-(4-chlorophenyl){4-[(4-ethoxycarbonyl-piperazinyl)methyl]phenyl}methyl}}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine,
    • 1-{(RS)-(4-chlorophenyl)[4-(N-cyclopropyl-N-propylaminomethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine,
    • 1-{(R)-(4-chlorophenyl)[4-(N-cyclopropyl-N-propylaminomethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine,
    • 1-{(S)-(4-chlorophenyl)[4-(N-cyclopropyl-N-propylaminomethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine,
    • 1-{(RS)-(4-chlorophenyl)[4-(diisopropylamino-methyl)phenyl]methyl}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine,
    • 1-{(R)-(4-chlorophenyl)[4-(diisopropylaminomethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-sulfonyl)methylene]azetidine,
    • 1-[(S)-(4-chlorophenyl)[4-(diisopropylaminomethyl)-phenyl]methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)-methylene]azetidine,
    • 1-{{(RS)-(4-chlorophenyl){4-[bis(2-methoxyethyl)-aminomethyl]phenyl}methyl}}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine,
    • 1-{{(R)-(4-chlorophenyl){4-[bis(2-methoxyethyl)-aminomethyl]phenyl}methyl}}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine,
    • 1-{{(S)-(4-chlorophenyl){4-[bis(2-methoxyethyl)-aminomethyl]phenyl}methyl}}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine,
    • 1-{(RS)-(4-chlorophenyl)[4-[di-n-propylaminomethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl](methylsulfonyl)methylene]azetidine,
    • 1-{(R)-(4-chlorophenyl)[4-(di-n-propylaminomethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)-methylene]azetidine,
    • 1-{(S)-(4-chlorophenyl)[4-(di-n-propylaminomethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-sulfonyl)methylene]azetidine,
    • 1-{(RS)-(4-chlorophenyl)[4-(piperidin-1-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-sulfonyl)methylene]azetidine,
    • 1-{(R)-(4-chlorophenyl)[4-(piperidin-1-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-sulfonyl)methylene]azetidine,
    • 1-{(S)-(4-chlorophenyl)[4-(piperidin-1-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-sulfonyl)methylene]azetidine,
    • 1-{(RS)-(4-chlorophenyl)[4-(4-methylpiperazin-1-ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine,
    • 1-{(R)-(4-chlorophenyl)[4-(4-methylpiperazin-1-ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine,
    • 1-{(S)-(4-chlorophenyl)[4-(4-methylpiperazin-1-ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine,
    • 1-{(RS)-(4-chlorophenyl)[4-(morpholin-4-ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine,
    • 1-{(R)-(4-chlorophenyl)[4-(morpholin-4-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine,
    • 1-{(S)-(4-chlorophenyl)[4-(morpholin-4-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine,
    • 1-{(RS)-(4-chlorophenyl)[4-(diethylaminomethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-sulfonyl)methylene]azetidine,
    • 1-{(R)-(4-chlorophenyl)[4-(diethylaminomethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-sulfonyl)methylene]azetidine,
    • 1-{(S)-(4-chlorophenyl)[4-(diethylaminomethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-sulfonyl)methylene]azetidine,
    • 1-{(RS)-(4-chlorophenyl)[4-(piperazin-2-one-4-ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-sulfonyl)methylene]azetidine,
    • 1-{(R)-(4-chlorophenyl)[4-(piperazin-2-one-4-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-sulfonyl)methylene]azetidine,
    • 1-{(S)-(4-chlorophenyl)[4-(piperazin-2-one-4-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-sulfonyl)methylene]azetidine,
    • 1-{(RS)-(4-chlorophenyl)[4-(imidazol-1-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-sulfonyl)methylene]azetidine,
    • 1-{(R)-(4-chlorophenyl)[4-(imidazol-1-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-sulfonyl)methylene]azetidine,
    • 1-{(S)-(4-chlorophenyl)[4-(imidazol-1-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-sulfonyl)methylene]azetidine,
    • (RS)-1-{(4-chlorophenyl)[4-(N,N-dimethylcarbamoyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine,
    • (R)-1-{(4-chlorophenyl)[4-(N,N-dimethylcarbamoyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine,
    • (S)-1-{(4-chlorophenyl)[4-(N,N-dimethylcarbamoyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine,
    • (RS)-1-{(4-chlorophenyl)[4-(N-ethylcarbamoyl)phenyl]methyl)}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine,
    • (R)-1-{(4-chlorophenyl)[4-(N-ethylcarbamoyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine,
    • (S)-1-{(4-chlorophenyl)[4-(N-ethylcarbamoyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine,
    • (RS)-1-[(4-carbamoylphenyl)(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-azetidine,
    • (R)-1-[(4-carbamoylphenyl)(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-azetidine,
    • (S)-1-[(4-carbamoylphenyl)(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-azetidine,
    • 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-dichloro-phenyl)(methylsulfonyl)methylene]azetidine,
    • 1-benzhydryl-3-[(3-methylsulfanylphenyl)(methyl-sulfonyl)methylene]azetidine,
    • 1-benzhydryl-3-[(3-methylsulfanylmethyl)phenyl)]-(methylsulfonyl)methylene]azetidine,
    • 1-[bis(4-chlorophenyl)methyl]-3-[(3-cyanophenyl)-(methylsulfonyl)methylene]azetidine,
    • 1-[bis(4-chlorophenyl)methyl]-3-[(3-carbamoylphenyl)-(methylsulfonyl)methylene]azetidine,
    • 1-[bis(4-chlorophenyl)methyl]-3-[(3-methoxyphenyl)-(methylsulfonyl)methylene]azetidine,
    • 1-[bis(4-chlorophenyl)methyl]-3-[(3-hydroxyphenyl)-(methylsulfonyl)methylene]azetidine,
    • 1-[bis(4-chlorophenyl)methyl]-3-[(methylsulfonyl)(3-pyrrolidinylphenyl)methylene]azetidine,
    • 1-[bis(4-chlorophenyl)methyl]-3-[(3-hydroxy-(methylphenyl)(methylsulfonyl)methylene]azetidine,
    • 1-[bis(4-chlorophenyl)methyl]-3-{(methylsulfonyl)[3-(N-piperidylcarbamoyl)phenyl]methylene}azetidine,
    • 1-[bis(4-chlorophenyl)methyl]-3-[(methylsulfonyl)(3-trifluoromethylsulfanylphenyl)(methylsulfonyl)-methylene]azetidine,
    • 1-[bis(4-fluorophenyl)methyl]-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine,
    • 1-[bis(2-fluorophenyl)methyl]-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine,
    • 1-[bis(3-fluorophenyl)methyl]-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine,
    • (RS)-1-[(4-chlorophenyl)(thiazol-2-yl)methyl]-3-[(methylsulfonyl)(phenyl)methylene]azetidine,
    • (R)-1-[(4-chlorophenyl)(thiazol-2-yl)methyl]-3-[(methylsulfonyl)(phenyl)methylene]azetidine,
    • (S)-1-[(4-chlorophenyl)(thiazol-2-yl)methyl]-3-[(methylsulfonyl)(phenyl)methylene]azetidine,
    • (RS)-1-[(4-chlorophenyl)(thien-2-yl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine,
    • (R)-1-[(4-chlorophenyl)(thien-2-yl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine,
    • (S)-1-[(4-chlorophenyl)(thien-2-yl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine,
    • 1-benzhydryl-3-[(ethylsulfonyl)(phenyl)methylene]-azetidine,
    • 1-[bis(4-chlorophenyl)methyl]-3-{{3-[N-(4-methylpiperazinyl)carbamoyl]phenyl}(methylsulfonyl)-methylene}azetidine,
    • 1-[bis(4-chlorophenyl)methyl]-3-{[3-(2,2-dimethylcarbohydrazido)phenyl](methylsulfonyl)-methylene}azetidine,
    • 1-[bis(thien-2-yl)methyl]-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine,
    • 1-[bis(p-tolyl)methyl]-3-[(methylsulfonyl)-(phenyl)methylene]azetidine,
    • 1-[(4-chlorophenyl)(4-hydroxymethylphenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-azetidine,
    • 1-[bis(4-chlorophenyl)methyl]-3-[(3-methylaminophenyl)-(methylsulfonyl)methylene]azetidine,
    • (RS)-1-[(4-chlorophenyl)(thiazol-2-yl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine,
    • (R)-1-[(4-chlorophenyl)(thiazol-2-yl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine,
    • (S)-1-[(4-chlorophenyl)(thiazol-2-yl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine,
    • 1-[bis(4-chlorophenyl)methyl]-3-[(methylsulfonyl)(2-methoxycarbonylthien-5-yl)methylene]azetidine,
    • (RS)-1-[bis(4-chlorophenyl)methyl]-3-hydroxy-3-[(methylsulfonyl)(2-methoxycarbonylthien-5-yl)methyl]azetidine,
    • 1-[bis(4-chlorophenyl)methyl]-3-[(2-isobutylamino-carbonylthien-5-yl)(methylsulfonyl)methylene]azetidine,
    • 1-[bis(4-chlorophenyl)methyl]-3-[(RS)-(3-methoxy-carbonylphenyl)(methylsulfonyl)methyl]azetidin-3-ol,
    • 1-[bis(4-chlorophenyl)methyl]-3-[(RS)-(methyl-sulfonyl)(pyridin-4-yl)methyl]azetidin-3-ol,
    • 1-[bis(4-chlorophenyl)methyl]-3-[(RS)-(methylsulfonyl)(pyridin-3-yl)methyl]azetidin-3-ol,
    • 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(3-(morpholin-4-yl)propyl)benzamide,
    • 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(3-dimethylaminopropyl)benzamide,
    • 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)benzamide,
    • 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2-dimethylamino-1-methylethyl)benzamide,
    • 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(piperidin-1-yl)benzamide,
    • 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-isobutylbenzamide,
    • 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(3-(imidazol-1-yl)propyl)benzamide,
    • 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2-dimethylaminoethyl)benzamide,
    • N′-methylhydrazide of 3-({1-[bis(4-chlorophenyl)-methyl]azetidin-3-ylidene}(methanesulfonyl)-methyl)benzoic acid,
    • 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2-(morpholin-4-yl)ethyl)benzamide,
    • 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(1-ethylpyrrolidin-2-ylmethyl)benzamide,
    • 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2,2-dimethylpropyl)benzamide,
    • 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(cyclohexylmethyl)benzamide,
    • 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(cyclopropylmethyl)benzamide,
    • 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2-methylbutyl)benzamide,
    • 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2-phenylpropyl)benzamide,
    • 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(tetrahydrofuran-2-ylmethyl)benzamide,
    • 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2,2-diphenylethyl)benzamide,
    • 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2-ethylbutyl)benzamide,
    • methyl ester of 4-{[3-({1-[bis(4-chlorophenyl)methyl]-azetidin-3-ylidene}(methanesulfonyl)methyl)-benzoylamino]methyl}cyclohexanecarboxylic acid,
    • 2-amino-1-{4-[3-({1-[bis(4-chlorophenyl)methyl]-azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]-piperazin-1-yl}ethanone,
    • tert-butyl ester of (2-{4-[3-({1-[bis(4-chlorophenyl)-methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-phenyl]piperazin-1-yl}-2-oxoethyl)carbamic acid,
    • 1-{4-[3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]piperazin-1-yl}-2-(methylamino)ethanone,
    • tert-butyl ester of (2-{4-[3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]piperazin-1-yl}-2-oxoethyl)-N-methylcarbamic acid,
    • N-methylamide of 4-[3-({1-[bis(4-chlorophenyl)-methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-phenyl]piperazine-1-carbothioic acid,
    • N-methylamide of 4-[3-({1-[bis(4-chlorophenyl)methyl]-azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]-piperazine-1-carboxylic acid, methyl ester of 4-[3-({1-[bis(4-chlorophenyl)methyl]-azetidin-3-ylidene}(methanesulfonyl)methyl)-phenyl]piperazine-1-carboxylic acid,
    • 1-[3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]-4-isobutylpiperazine,
    • 1-[3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]-4-ethylpiperazine,
    • 4-acetyl-1-[3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]piperazine,
    • 1-{4-[3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]piperazin-1-yl}-2-dimethylaminoethanone,
    • 1-[3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]piperazine, tert-butyl ester of 4-[3-({1-[bis(4-chlorophenyl)-methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-phenyl]piperazine-1-carboxylic acid,
    • 1-[bis(4-methoxycarbonylphenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine,
    • 3-acetoxy-1-[bis(4-methoxycarbonylphenyl)methyl]-3-[(RS)-(3,5-difluorophenyl)(methylsulfonyl)methyl]-azetidine,
    • (RS)-4-[4-((4-chlorophenyl){3-[(3,5-difluorophenyl)(methanesulfonyl)methylene]azetidin-1-yl}methyl)benzyl]morpholine,
    • 4-(4-{3-[(1-benzhydrylazetidin-3-ylidene)(methane-sulfonyl)methyl]phenoxy}butyl)morpholine,
    • 4-(4-{3-[(1-benzhydrylazetidin-3-ylidene)(methane-sulfonyl)methyl]phenoxy}propyl)morpholine,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}thien-2-ylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-4-methoxyphenylsulfonamide,
    • N-[4-(N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-sulfamoyl)phenyl]acetamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-4-methylphenylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3,4-dimethoxyphenylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-fluorophenylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3,4-dichlorophenylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-cyanophenylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-2,5-dimethoxyphenylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-trifluoromethylphenylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}naphth-2-ylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}naphth-1-ylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3,4-difluorophenylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-1-methyl-1H-imidazol-4-ylsulfonamide,
    • N-[4-(N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}sulfamoyl)-2-chlorophenyl]acetamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}pyrid-3-ylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-4-fluorophenylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}quinol-8-ylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}phenylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}(phenylmethyl)sulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3,5-difluorophenylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}pyrid-2-ylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-(3-fluoro-5-pyrrolidin-1-ylphenyl)sulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-methyl-4-fluorophenylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-methylquinol-8-ylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-methylphenylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-methyl(phenylmethyl)sulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-sulfamoylphenylsulfonamide,
    • 2-benzenesulfonyl-N-{1-[bis(4-chlorophenyl)methyl]-azetidin-3-yl}acetamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-2-(4-toluene-4-sulfonyl)acetamide,
    • (3-chloro-4-(methylsulfonyl)thiophene-2-carboxy)-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}amide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-(2-phenylethylenesulfonyl)propionamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-4-(methylsulfonyl)benzamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-4-(methanesulfonyl)benzamide,
    • (5-(methylsulfonyl)thiophene-2-carboxy)-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}amide,
    • (5-methylsulfonyl-3-methyl-4-vinylthiophene-2-carboxy){1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}amide,
    • (RS)—N-{1-[(4-chlorophenyl)(pyridin-3-yl)methyl]-azetidin-3-yl}-3,5-difluorobenzenesulfonamide,
    • (RS)—N-{1-[(4-chlorophenyl)(pyrimidin-5-yl)methyl]-azetidin-3-yl}-3,5-difluorobenzenesulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(6-chloropyrid-2-yl)methylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(6-ethylpyrid-2-yl)methylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(quinol-6-yl)methylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(quinol-5-yl)methylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(isoquinol-5-yl)methylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-yl)methylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-1-oxide-3-yl)methylsulfonamide,
    • N-(1R,2S,4S)-(bicyclo[2.2.1]hept-2-yl)-N-{1-[bis-(4-chlorophenyl)methyl]azetidin-3-yl}methylsulfonamide,
    • N-(1R,2R,4S)-(bicyclo[2.2.1]hept-2-yl)-N-{1-[bis-(4-chlorophenyl)methyl]azetidin-3-yl}methylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(thiazol-2-yl)methylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3-methoxyphenyl)methylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3-hydroxyphenyl)methylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3-(hydroxymethyl)phenyl)methylsulfonamide, ethyl N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(methylsulfonyl)-3-aminobenzoate,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(isobutylpiperid-4-yl)methylsulfonamide,
    • N-benzyl-N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}amine,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorobenzyl)amine,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorobenzyl)methylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-ylmethyl)methylsulfonamide,
    • N-{1-[bis(4-fluorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide,
    • (RS)—N-{1-[(4-chlorophenyl)(pyrid-3-yl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide,
    • (R)—N-{1-[(4-chlorophenyl)(pyrid-3-yl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide,
    • (S)—N-{1-[(4-chlorophenyl)(pyrid-3-yl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide,
    • (RS)—N-{1-[(4-chlorophenyl)(pyrid-4-yl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide,
    • (R)—N-{1-[(4-chlorophenyl)(pyrid-4-yl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide,
    • (S)—N-{1-[(4-chlorophenyl)(pyrid-4-yl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide,
    • (RS)—N-{1-[(4-chlorophenyl)(pyrimidin-5-yl)methyl]-azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide,
    • (R)—N-{1-[(4-chlorophenyl)(pyrimidin-5-yl)methyl]-azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide,
    • (S)—N-{1-[(4-chlorophenyl)(pyrimidin-5-yl)methyl]-azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide,
    • N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)benzylsulfonamide,
      their optical isomers and their pharmaceutically acceptable salts with an inorganic or organic acid.
  • And even more particularly preferred are the following azetidine derivatives:
    • 1-[bis(4-chlorophenyl)methyl]-3-[(RS)-(3,5-difluoro-phenyl)(methylsulfonyl)methyl]azetidin-3-ol,
    • 3-acetoxy-1-[bis(4-chlorophenyl)methyl]-3-[(RS)-(3,5-difluorophenyl)(methylulphonyl)methyl)methylsulfon ylmethyl]azetidine,
    • 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, their optical isomers and their pharmaceutically acceptable salts with an inorganic or organic acid.
  • Mention may be made, as examples of pharmaceutically acceptable salts of the azetidine derivatives, of the following salts: benzenesulfonate, hydrobromide, hydrochloride, citrate, ethanesulfonate, fumarate, gluconate, iodate, isethionate, maleate, methanesulfonate, methylenebis-β-oxynaphthoate, nitrate, oxalate, pamoate, phosphate, salicylate, succinate, sulfate, tartrate, theophyllinacetate and p-toluenesulfonate.
  • Other CB1 receptor antagonists of use in the combinations according to the invention are, for example, the pyrazole derivatives disclosed in EP 576 357, EP 658 546, EP 656 354, WO 97/19063 and WO 00/46209, the benzothiophene and benzofuran derivatives disclosed in WO 96/02248 or the arylsulfonamides disclosed in WO 98/37061. Mention may in particular be made of the products known under the code SR141716 (N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide) and LY320135. All of the references described herein are incorporated herein by reference in their entirety.
  • The synergistic effect of the combination of sibutramine and of a CB1 receptor antagonist on food intake was determined according to the following protocol:
  • Obese Fa/fa Zucker rats aged 7 weeks and originating from Iffa-Credo, France, were used in this study. The rats are housed in individual cages and weighed every day between 8 and 10 o'clock in the morning. The amount of food is also weighed each morning at the same time. This food (M20, Pietrement, France) is changed every day and the rats have free access thereto for 24 hours. All the rats are treated for a week with the vehicle (miglyol 812N and 0.5% methylcellulose/0.2% polysorbate 80) in two consecutive administrations. The rats are treated from the 8th day with the vehicle, the CB1 receptor antagonist (1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine) or sibutramine by the oral route (see table below).
  • The sibutramine is dissolved in a 0.5% methylcellulose/0.2% polysorbate 80 solution and administered at a dose of 3 mg/kg; the CB1 receptor antagonist is dissolved in miglyol 812N (Hüls, Germany) at a dose of 0.6 mg/kg and the two products are administered under a volume of 1 ml/kg. Each group is composed of 12 to 14 animals. The following groups are formed and the animals are treated for five days at the rate of two consecutive administrations every day.
    First Second
    GROUP administration administration
    1 miglyol 0.5% methylcellulose/
    “vehicle group” 0.2% polysorbate
    2 miglyol sibutramine 3 mg/kg
    “sibutramine
    group”
    3 CB1 receptor 0.5% methylcellulose/
    “CB1 receptor antagonist 0.2% polysorbate
    antagonist 0.6 mg/kg
    group”
    4 CB1 receptor sibutramine 3 mg/kg
    “combination antagonist
    group” 0.6 mg/kg
  • The food consumption of each animal is measured every day. The results are expressed as mean amount of food consumed during the 5 days of treatment. The results obtained are given in the table below.
    Food consumption during the
    Treatment 5 days of treatment (g)
    Vehicles 25.52 ± 0.30
    sibutramine 3 mg/kg  24.60 ± 0.32*
    CB1 receptor antagonist  24.00 ± 0.24**
    0.6 mg/kg
    sibutramine (3 mg/kg) + CB1   22.76 ± 0.02***
    receptor antagonist
    (0.6 mg/kg)

    *p < 0.05

    **p < 0.01

    ***p < 0.0001
  • The results show that, in the animals receiving the sibutramine and CB1 receptor antagonist combination, the reduction in food consumption is much greater has that of the animals treated either with sibutramine alone or with the CB1 receptor antagonist alone.
  • The compounds of the combination can be employed orally, parenterally, transdermally or rectally, either simultaneously or separately or spread out over time.
  • The present invention also relates to the pharmaceutical compositions comprising the combination of sibutramine, its hydrate or one of its pharmaceutically acceptable salts and of a CB1 receptor antagonist in the pure state or with one or more compatible and pharmacologically acceptable diluents and/or adjuvants and/or optionally in combination with another pharmaceutically compatible and physiologically active product for a use which is either simultaneous or separate or spread out over time.
  • Use may be made, as solid compositions for oral administration, of tablets, pills, powders (hard gelatin capsules, cachets) or granules. In these compositions, the active principles are mixed with one or more inert diluents, such as starch, cellulose, sucrose, lactose or silica, under an argon stream. These compositions can also comprise substances other than the diluents, for example one or more lubricants such as magnesium stearate or talc, a colorant, a coating (dragées) or a glaze.
  • Use may be made, as liquid compositions for oral administration, of pharmaceutically acceptable solutions, suspensions, emulsions, syrups and elixirs comprising inert diluents, such as water, ethanol, glycerol, vegetable oils or liquid paraffin. These compositions can comprise substances other than the diluents, for example wetting, sweetening, thickening, flavoring or stabilizing products.
  • The sterile compositions for parenteral administration can preferably be solutions in aqueous or nonaqueous form, suspensions or emulsions. Use may be made, as solvent or vehicle, of water, propylene glycol, a polyethylene glycol, vegetable oils, in particular olive oil, injectable organic esters, for example ethyl oleate, or other suitable organic solvents. These compositions can also comprise adjuvants, in particular wetting, isotonizing, emulsifying, dispersing and stabilizing agents. Sterilization can be carried out in several ways, for example by aseptic filtration, by incorporating sterilizing agents in the composition, by irradiation or by heating. They can also be prepared in the form of sterile solid compositions which can be dissolved at the time of use in sterile water or any other injectable sterile medium.
  • The compositions for rectal administration are suppositories or rectal capsules which comprise, in addition to the active product, excipients such as cocoa butter, semisynthetic glycerides or polyethylene glycols.
  • The pharmaceutical compositions generally comprise 0.5 to 10 mg of sibutramine and 0.1 to 200 mg of the CB1 receptor antagonist.
  • The present invention also relates to the method for the treatment of obesity which consists in administering, to the patient, a combination according to the invention either simultaneously or separately or spread out over time.
  • The doses depend on the desired effect, on the duration of treatment and on the administration route used; they are generally from 1 to 15 mg of sibutramine per day by the oral route for an adult and from 0.10 to 500 mg of the CB1 receptor antagonist per day by the oral route for an adult.
  • Generally, the doctor will determine the appropriate dosage according to the age, weight and any other factor specific to the subject to be treated.

Claims (15)

1. A combination of a CB1 receptor antagonist or a hydrate or a pharmaceutically acceptable salt thereof and sibutramine or a hydrate or a pharmaceutically acceptable salt thereof.
2. The combination according to claim 1, wherein the CB1 receptor antagonist is: N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide or a pharmaceutically acceptable salt thereof.
3. The combination according to claim 1, wherein the components of the combination are administered simultaneously, separately or spread out over time.
4. The combination according to claim 1, wherein each component of the combination is administered in a single dose or in multiple doses.
5. A composition comprising a CB1 receptor antagonist or a hydrate or a pharmaceutically acceptable salt thereof and sibutramine or a hydrate or a pharmaceutically acceptable salt thereof, and at least one compatible and pharmacologically acceptable diluent or adjuvant.
6. The composition according to claim 5, wherein the CB1 receptor antagonist is: N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide or a pharmaceutically acceptable salt thereof.
7. The composition according to claim 5, comprising 0.5 to 10 mg of sibutramine and 0.1 to 200 mg of the CB1 receptor antagonist.
8. The composition according to claim 5, further in combination with a pharmaceutically compatible and physiologically active product.
9. The composition according to claim 6, further in combination with a pharmaceutically compatible and physiologically active product.
10. A process for treating obesity in a mammal, comprising administering to said mammal an effective amount of at least one CB1 receptor antagonist or a hydrate or a pharmaceutically acceptable salt thereof and sibutramine or a hydrate or a pharmaceutically acceptable salt thereof.
11. The process according to claim 10, wherein the CB1 receptor antagonist is: N-piperidino-5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide or a pharmaceutically acceptable salt thereof.
12. The process according to claim 10, wherein sibutramine is administered at a concentration ranging from 0.5 to 10 mg and the CB1 receptor antagonist is administered at a concentration ranging from 0.1 to 200 mg.
13. The process according to claim 10, wherein the CB1 receptor antagonist and sibutramine are administered simultaneously, separately or spread out over time.
14. The process according to claim 10, wherein the CB1 receptor antagonist is administered in a single dose or in multiple doses.
15. The process according to claim 10, wherein sibutramine is administered in a single dose or in multiple doses.
US11/937,121 2000-10-04 2007-11-08 Combination of a cb1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity Abandoned US20080058381A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/937,121 US20080058381A1 (en) 2000-10-04 2007-11-08 Combination of a cb1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
FR0012646 2000-10-04
FR0012646A FR2814678B1 (en) 2000-10-04 2000-10-04 COMBINATION OF AN ANTAGONIST OF THE CB1 RECEPTOR AND SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE FOR THE TREATMENT OF OBESITY
US24418700P 2000-10-31 2000-10-31
US09/968,903 US20020091114A1 (en) 2000-10-04 2001-10-03 Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
US10/941,242 US7148258B2 (en) 2000-10-04 2004-09-15 Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
US11/461,468 US20060258709A1 (en) 2000-10-04 2006-08-01 Combination of a cb1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
US11/937,121 US20080058381A1 (en) 2000-10-04 2007-11-08 Combination of a cb1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/461,468 Continuation US20060258709A1 (en) 2000-10-04 2006-08-01 Combination of a cb1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity

Publications (1)

Publication Number Publication Date
US20080058381A1 true US20080058381A1 (en) 2008-03-06

Family

ID=27248705

Family Applications (5)

Application Number Title Priority Date Filing Date
US09/968,903 Abandoned US20020091114A1 (en) 2000-10-04 2001-10-03 Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
US10/941,242 Expired - Fee Related US7148258B2 (en) 2000-10-04 2004-09-15 Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
US10/941,190 Expired - Fee Related US7037944B2 (en) 2000-10-04 2004-09-15 Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
US11/461,468 Abandoned US20060258709A1 (en) 2000-10-04 2006-08-01 Combination of a cb1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
US11/937,121 Abandoned US20080058381A1 (en) 2000-10-04 2007-11-08 Combination of a cb1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity

Family Applications Before (4)

Application Number Title Priority Date Filing Date
US09/968,903 Abandoned US20020091114A1 (en) 2000-10-04 2001-10-03 Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
US10/941,242 Expired - Fee Related US7148258B2 (en) 2000-10-04 2004-09-15 Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
US10/941,190 Expired - Fee Related US7037944B2 (en) 2000-10-04 2004-09-15 Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
US11/461,468 Abandoned US20060258709A1 (en) 2000-10-04 2006-08-01 Combination of a cb1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity

Country Status (1)

Country Link
US (5) US20020091114A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050080125A1 (en) * 2003-09-03 2005-04-14 Jochen Antel Novel medical uses of 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
US20050124660A1 (en) * 2003-10-27 2005-06-09 Jochen Antel Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
US20050143441A1 (en) * 2003-10-27 2005-06-30 Jochen Antel Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
US20060128673A1 (en) * 2004-10-25 2006-06-15 Michael Firnges Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions
US20070191506A1 (en) * 2006-02-13 2007-08-16 3M Innovative Properties Company Curable compositions for optical articles
US9238027B2 (en) 2009-01-12 2016-01-19 Fundacion Del Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion (Fuhnpaiin) Use of CB1 antagonists and/or inverse agonists for the preparation of drugs that increase motor neuron excitability

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US20030139386A1 (en) * 2001-12-21 2003-07-24 Sophie Cote Pharmaceutical compositions based on azetidine derivatives
CA2478183C (en) * 2002-03-12 2010-02-16 Merck & Co. Inc. Substituted amides
US20040077650A1 (en) * 2002-10-18 2004-04-22 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
FR2849032B1 (en) * 2002-12-23 2006-04-28 Sanofi Synthelabo 5- (4-BROMOPHENYL) -1- (2,4-DICHLOROPHENYL) -4-ETHYL-N - (PIPERIDIN-1-YL) -1H-PYRAZOLE-3-CARBOXAMIDE DERIVATIVE, ITS PREPARATION, ITS THERAPEUTIC APPLICATION
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
WO2004099157A1 (en) * 2003-05-07 2004-11-18 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US20040259887A1 (en) * 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
FR2861303A1 (en) * 2003-10-24 2005-04-29 Sanofi Synthelabo Use of pyrazole derivative as cannabinoid CB1 receptor antagonist, for treatment and prevention of metabolic syndrome, particularly cardiovascular risks, dyslipidemia and liver disease associated with obesity
ES2244314B1 (en) * 2004-02-17 2007-02-01 Laboratorios Del Dr. Esteve, S.A. SUBSTITUTED AZETIDINIC COMPOUNDS, THEIR PREPARATION AND THEIR APPLICATION AS MEDICATIONS.
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
WO2006124506A2 (en) * 2005-05-13 2006-11-23 Abbott Laboratories Combination and use of drugs
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118853A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2007118854A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
US7629346B2 (en) * 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
US7781593B2 (en) * 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US8580298B2 (en) * 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
WO2010093243A1 (en) 2009-02-12 2010-08-19 Coöperatieve Mirzorg U.A., Arnhem Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
NL2022615B1 (en) 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462960A (en) * 1993-12-17 1995-10-31 Sanofi Pyrazole-3-carboxamide derivatives, process for their preparation and pharmaceutical compositions in which they are present
US5624941A (en) * 1992-06-23 1997-04-29 Sanofi Pyrazole derivatives, method of preparing them and pharmaceutical compositions in which they are present
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
US6479479B2 (en) * 2000-03-03 2002-11-12 Aventis Pharma S.A. Azetidine derivatives, their preparation and pharmaceutical compositions containing them
US6518264B2 (en) * 1998-09-11 2003-02-11 Aventis Pharma S.A. Azetidine derivatives, their preparation and medicaments containing them

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE61928B1 (en) 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
EP0454734A4 (en) 1989-01-19 1992-03-11 David Sarnoff Research Center Devitrifying glass formulations for low expansion printed-circuit substrates and inks
FR2713225B1 (en) 1993-12-02 1996-03-01 Sanofi Sa Substituted N-piperidino-3-pyrazolecarboxamide.
IL111959A (en) 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them
US5596106A (en) 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2741621B1 (en) 1995-11-23 1998-02-13 Sanofi Sa NOVEL PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
EP0969852A4 (en) 1996-10-31 2004-05-06 Merck & Co Inc Combination therapy for the treatment of diabetes and obesity
FR2758723B1 (en) 1997-01-28 1999-04-23 Sanofi Sa USE OF CENTRAL CANNABINOID RECEPTOR ANTAGONISTS FOR THE PREPARATION OF DRUGS
DK0966436T3 (en) 1997-02-21 2003-03-31 Bayer Ag Arylsulfonamides and analogs thereof and their use in the treatment of neurodegenerative disorders
NL1010120C2 (en) 1998-09-17 2000-03-21 Foodcorner International B V Slice carrier for foodstuffs as well as method and device for making the slice carrier.
US6518284B2 (en) * 1998-11-18 2003-02-11 Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. 4-substituted piperidines
KR100334993B1 (en) * 1998-12-01 2002-05-02 추후제출 Heater
FR2789079B3 (en) 1999-02-01 2001-03-02 Sanofi Synthelabo PYRAZOLECARBOXYLIC ACID DERIVATIVE, ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
WO2001015609A1 (en) 1999-08-31 2001-03-08 Fox Hollow Technologies Atherectomy catheter with a rotating and telescoping cutter
FR2805817B1 (en) 2000-03-03 2002-04-26 Aventis Pharma Sa PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND THEIR PREPARATION
JP4873335B2 (en) 2000-04-28 2012-02-08 独立行政法人科学技術振興機構 Information processing structure

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624941A (en) * 1992-06-23 1997-04-29 Sanofi Pyrazole derivatives, method of preparing them and pharmaceutical compositions in which they are present
US5462960A (en) * 1993-12-17 1995-10-31 Sanofi Pyrazole-3-carboxamide derivatives, process for their preparation and pharmaceutical compositions in which they are present
US6518264B2 (en) * 1998-09-11 2003-02-11 Aventis Pharma S.A. Azetidine derivatives, their preparation and medicaments containing them
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
US6479479B2 (en) * 2000-03-03 2002-11-12 Aventis Pharma S.A. Azetidine derivatives, their preparation and pharmaceutical compositions containing them

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050080125A1 (en) * 2003-09-03 2005-04-14 Jochen Antel Novel medical uses of 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
US20050239859A2 (en) * 2003-09-03 2005-10-27 Solvay Pharmaceuticals Gmbh Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity
US20050124660A1 (en) * 2003-10-27 2005-06-09 Jochen Antel Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
US20050143441A1 (en) * 2003-10-27 2005-06-30 Jochen Antel Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
US20060128673A1 (en) * 2004-10-25 2006-06-15 Michael Firnges Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions
US8058264B2 (en) 2004-10-25 2011-11-15 Abbott Products Gmbh Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions
US20070191506A1 (en) * 2006-02-13 2007-08-16 3M Innovative Properties Company Curable compositions for optical articles
US7767728B2 (en) * 2006-02-13 2010-08-03 3M Innovative Properties Company Curable compositions for optical articles
US9238027B2 (en) 2009-01-12 2016-01-19 Fundacion Del Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion (Fuhnpaiin) Use of CB1 antagonists and/or inverse agonists for the preparation of drugs that increase motor neuron excitability
US9592237B2 (en) 2009-01-12 2017-03-14 Fundacion Del Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion (Fuhnpaiin) Use of CB1 antagonists and/or inverse agonists for the preparation of drugs that increase motor neuron excitability

Also Published As

Publication number Publication date
US7037944B2 (en) 2006-05-02
US20060258709A1 (en) 2006-11-16
US7148258B2 (en) 2006-12-12
US20050032773A1 (en) 2005-02-10
US20020091114A1 (en) 2002-07-11
US20050032774A1 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
US7148258B2 (en) Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
AU2001293936B2 (en) Association of the CB1 receptor antagonist and sibutramin, for treating obesity
US7105504B2 (en) Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson&#39;s disease
JP3676383B2 (en) Use of central cannabinoid receptor antagonists to control appetite
US20070197654A1 (en) Combination of a cb1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson&#39;s disease
JP2005505539A5 (en)
JP2003522145A (en) Use of central cannabinoid receptor antagonists in pharmaceuticals to help stop tobacco consumption
SK12352001A3 (en) Use of one or more agents or compounds simultaneously or sequentially acting on 5-ht3 receptors, 5-ht4 receptors and on proton pump or h2 receptors for the treatment of gastrointestinal disorders and pharmaceutical composition
RU2008127491A (en) APPLICATION OF CB1 ANTAGONIST FOR TREATMENT OF SIDE EFFECTS AND NEGATIVE SYMPTOMS OF SCHIZOPHRENIA
CN102387798A (en) Methods of using and compositions comprising PDE4 modulators for treatment, prevention and management of tuberculosis
HRP980023A2 (en) Use of beta3-adrenergic receptor antagonists for the preparation of healing drugs
JP2021031393A (en) Therapeutic agent for hanging neck syndrome
US20070043111A1 (en) Use of ifenprodril in the treatment of pain
EP1097698A2 (en) Utilization of derivatives of tetrahydropyridines (or 4-hydroxypiperidines)-butylazols in the preparation of a medicament for the treatment of pain
CN105873611A (en) Compositions and methods for the treatment of viral diseases with PDE4 modulators

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION